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Abstract Fibrillin-1 is a major constituent of tissue microfibrfls 
that occur in most connective tissues, either in close association 
with or independent of elastin. To test possible cell-adhesive 
functions of this protein, we used recombinant human fibrlllin-1 
polypeptides produced in a mammalian expression system in cell 
attachment and solid-phase integrin binding assays. Fibrillin-1 
polypeptides containing the single RGD sequence located in the 
fourth 8-eysteine domain, mediated distinct cell adhesion of a 
variety of cell lines and bound to purified integrin c~V[~3. 
Integrins otIIb[~3, c~5[~1, ~.[~1 and ~1151 did not interact with any 
of the recombinant fibrillin-1 peptides. Our results indicate a 
novel role for fibrillin-1 in cellular interactions mediated via an 
RGD motif that is appropriately exposed for recognition by 
integrin c¢VI53. 
necessitates the use of buffers containing denaturing agents 
and cannot separate fibrillin-1 and fibrillin-2 [18], we chose 
to use recombinant human fibrillin-1 polypeptides for a study 
of possible cell-adhesive functions. These human fibrillin-1 
peptides were produced in a mammalian expression system 
and purified under non-denaturing conditions [19]. Extensive 
characterization i dicated correct folding [19]. Using an ex- 
perimental approach already applied to characterize cell-ad- 
hesive and integrin-binding functions of fibulins [20], laminin 
[21] and collagen VI [22], we demonstrate he ability of cells to 
adhere to fibrillin-1 via an RGD motif located in the fourth 8- 
cysteine domain. In addition we identify integrin aV[33 as a 
major cellular receptor for this site. 
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2. Materials and methods 
1. Introduction 
Fibrillins are a family of large extracellular glycoproteins, 
which are integral components of the 10-12 nm diameter mi- 
crofibrils found throughout the extracellular space, in elastic 
and non-elastic tissues [1,2]. So far two members of this fam- 
ily, fibrillin-1 [3-6] and fibrillin-2 [4,7], have been described as 
products of different genes. These proteins share a common 
organization of domains consisting mostly of calcium-binding 
EGF-like repeats and novel motifs containing 8 cysteines, 
which are also found in the family of TGF-13 binding proteins 
[3,5,8]. Also common to both proteins is the presence of RGD 
sequences suggesting possible interactions with integrin adhe- 
sion receptors [9]. 
In situ, microfibrils are often found in close proximity to 
cells. They appear to connect endothelial cells to elastic fibers 
in the subendothelial matrix of the mouse aorta [10] and of 
lymphatic capillaries [11,12]. In the mouse aortic media the 
elastic laminae are linked to smooth muscle cells by bundles 
of microfibrils [13]. Furthermore in rat bone marrow, micro- 
fibrils appear to connect endothelial cells of the sinusoidal 
wall to adventitial reticular cells [14] and in skin, microfibrils 
often extend from the elastic fibers in the dermis to the base- 
ment membrane of the dermal-epidermal junction closely ap- 
proximating the epidermal cell layer [15,16]. Recently Kielty et 
al. [17] reported cell attachment of smooth muscle cells to 
isolated microfibrils. Thus evidence for cellular interactions 
with microfibrils is accumulating, however it remains unclear 
which microfibrillar component is responsible for this activity. 
As the purification of fibrillin from cell culture medium 
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2.1. Peptides and protein ligands 
Human plasma fibronectin (Behringwerke, Marburg) and fibrino- 
gen (Calbiochem, Bad Soden) were purchased. Vitronectin was pur- 
ified by heparin chromatography [23]. Synthetic fibrillin RGD pep- 
tides were produced in our own facilities and kindly provided by Dr. 
L. Moroder. Synthetic GRGDS was obtained from Bachem, Heidel- 
berg. 
2.2. Recombinant production of human fibrillin-1 fragments 
The construction of expression vectors from human fibrillin-1 
cDNA, the transfection ofhuman fibrosarcoma HT1080 or embryonic 
kidney 293 cells and the purification and functional characterization 
of the recombinant proteins have been described in detail elsewhere 
[19]. Recombinant fibrillin-1 peptides were purified from culture 
supernatants under non-denaturing conditions and were considered 
>95% homogeneous based on their appearance in SDS polyacryla- 
mide gel electrophoresis. The correct structure was verified by Edman 
degradation, glycosylation a alysis, rotary shadowing, analysis of cys- 
teines, and by functional characterization, including Ca 2+ binding and 
binding of monoclonal ntibodies [19]. 
2.3. Cell attachment assays 
Adhesion of established cell lines to ligand-coated plastic wells for 
30q50 min followed by a colorimetric detection of bound cells was 
performed according to a previously published protocol [24]. In in- 
hibition experiments, cells were incubated for 10 min at 37°C with 
peptide inhibitors or blocking monoclonal antibodies [22] prior to 
adding to the coated wells. 
2.4. Solid phase binding assays with purified integrins 
The purification of human integrins etl[~l, c~2131, et5131, ccVI33, and 
~IIbl]3, as well as the protocol for solid phase binding assays with 
purified integrins i  outlined in detail [21]. Binding was performed in 
0.05 M Tris-HCl, pH 7.4, 0.15 M NaC1, 1 mM MnCI2, 1 mM MgCI~, 
and 0.1 mM CaCI2, 0.02% Tween 20. Bound ligand was detected 
using polyclonal rabbit antibodies followed by peroxidase-labeled 
goat anti-rabbit IgG [21]. Fibrillin-1 fragments rF6 and rF6trunc 
were detected with a rabbit antiserum raised against rF6trunc. For 
rF11, monoclonal ntibodies 201 and 26 [19] were used and the extent 
of binding was monitored by parallel binding experiments u ing im- 
mobilized fibulin-2 as a positive control [25]. In inhibition experi- 
ments, immobilized integrins were preincubated with inhibitory pep- 
tides for 10 min prior to addition of the soluble ligand. 
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3. Results 
The domain structure of the recombinant human fibrillin-1 
peptides relevant o this study is depicted in Fig. 1. Together 
they span the whole fibrillin-1 molecule, rF2, rF6trunc and 
rF6 are extensions from a central EGF-like motif adjacent 
to the fourth 8-cysteine domain, which contains the RGD 
motif. The small fragment rF2 (30 kDa) extends to the 
EGF-like repeat C-terminal to the fourth 8-cysteine domain. 
The large protein rF6 (195 kDa) includes the complete C- 
terminal half of fibrillin-1 and a truncated product rF6trunc 
(115 kDa) extends to the sixth 8-cysteine domain. Only the 
large N-terminal fragment rF l l  does not include the RGD 
motif. 
These polypeptides were immobilized on plastic and used in 
cell attachment assays (Fig. 2, Table 1). Distinct adhesion and 
spreading to fragments rF6 and rF6trunc was observed, 
although the overall extent of attachment compared to refer- 
ence ligands vitronectin (Fig. 2) or fibronectin (Table 1) varied 
considerably with the cell line. The large N-terminal fragment 
rF11 (Table 1) as well as the short polypeptide rF2 (data not 
shown) were inactive in these assays. However, rF2 was a 
highly active soluble inhibitor of A375 cell adhesion to 
rF6trunc (Table 2) indicating its inactivation by immobiliza- 
tion onto plastic. The synthetic peptides GRGDS and 
IRPRGDNGD representing the authentic fibrillin-1 sequence 
also totally inhibited A375 cell adhesion to rF6trunc (Table 
2). Complete inhibition by GRGDS at less than 30 gM was 
also observed for the attachment of A375, 251MG and A431 
cells on rF6. RGES as a control peptide (1 mM) was not 
inhibitory. Furthermore 251MG cell adhesion to rF6 could 
be blocked by at least 50% by adding inhibitory monoclonal 
antibodies pecific for the human 1~3-integrin subunit (C17) 
(data not shown). 
In order to identify possible cellular eceptors for fibrillin-1 
we performed solid phase binding assays with purified integ- 
rins. Integrins ¢zlIb[33 (Fig. 3A), ¢x5131, ¢x2131 and ¢z1131 (data 
not shown) did not interact with any fibrillin-1 polypeptide. In
contrast, integrin ¢xV133 (Fig. 3B) bound specifically to frag- 
ment rF6 and rF6trunc, but not to rF11, with either integrin 
(Fig. 3B) or fibrillin-1 polypeptide (not shown) used as the 
immobilized ligand. The specificity of this interaction is con- 
firmed by its sensitivity to the presence of 10 mM EDTA (not 
shown), and also by the inhibition with synthetic GRGDS 
and IRPRGDNGD peptides or with recombinant fragment 
fibrillin-1 
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Fig. 1. Domain structures of fibrillin-1 and the recombinant fibril- 
lin-1 polypeptides. The location of the RGD sequence is indicated. 
Numbers in brackets refer to the numbering of amino acids accord- 
ing to [6]. Due to an unexpected recombination event, fragment 
rF6trunc was found to contain a C-terminal 40-amino acid exten- 
sion derived from the major capsid protein VP1 of the SV40 virus. 
Verification of DNA sequences also revealed a point mutation in 
the DNA of fragment rF2 leading to an isoleucine to threonine 
change at position 1538 [19]. 
rF2 (Table 3). We also compared the inhibitory potential of 
RGD-containing nonapeptides representing sequences of hu- 
man fibrillin-1 (Fb-1) and fibrillin-2 (Fb-2/1 and Fb-2/2) in 
binding assays with three purified RGD-dependent integrins 
¢xV133, ~xlIb[33 and ¢x5131 and their ligands (Table 3). This 
revealed about 20-fold reduced inhibitory activities of the 
three nonapeptides compared to GRGDS with all three integ- 
rins. 
4. Discussion 
In this study, we have identified specific ell-adhesive activ- 
ity of three human recombinant fibrillin-1 polypeptides rF6, 
rF6trunc and rF2, all of which include the fourth 8-cysteine 
domain. This result, together with the potent and complete 
inhibition of adhesion with RGD peptides, locates the pri- 
Table 1 
Cell adhesion to recombinant human fibrillin-1 polypeptides 
Cell line rF11 rF6 rF6trunc 
251 MG astrocytoma < 5 91 113 
RN22 schwannoma <5 74 53 
A375 melanoma < 5 69 39 
HBL100 mammary epithelium <5 67 38 
A431 epidermoid < 5 67 25 
OVCAR-4 ovarian carcinoma <5 38 60 
Scl I epithelial carcinoma <5 23 23 
HT 1080 fibrosarcoma < 5 12 5 
Rugli glioblastoma < 5 < 5 < 5 
T47D mammary epithelium <5 <5 <5 
Fibroblasts adult skin <5 74 57 
Adhesion is expressed as % adhesion compared to fibronectin at 40 p.g/ml coating concentration. Cells were of human origin with the exception 
of RN22 and Rugli (rat). 
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Table 2 
Inhibition of A375 cell adhesion to vitronectin and rF6trunc by syn- 
thetic and recombinant RGD peptides 
Soluble inhibitor IC50 (gM) 
Vitronectin (2 gg/ml) rF6trunc (10 gg/ml) 
GRGDS 25 5.6 
IRPRGDNGD >200 120 
rF2 10 3.7 
Numbers in brackets indicate substrate concentrations u ed for coat- 
ing of plastic plates. 
mary site for fibrillin-1 cell binding to the single RGD se- 
quence in this domain. This RGD site is located in the middle 
of a 14-amino acid stretch flanked by two cysteines. Since all 8 
cysteines in the 8-cysteine domain are disulfide bonded [19], 
the RGD tripeptide is predicted to form the tip of a small 
loop structure• Available sequence data suggest hat this loop 
is conserved between species within fibrillin-1, and a similar 
RGD motif is present at the same position of fibrillin-2. The 
latter contains an additional RGD site in a different position 
of the third 8-cysteine domain [7], which is similarly located at 
the predicted tip of a small loop. 
In solid-phase binding assays with purified integrins we 
identified integrin c~VI33 as a potent binding partner for fibril- 
lin-1 fragment rF6, whereas two other RGD-binding integrins 
(txIIb[~3, ct5~l) and two collagen/laminin receptors (~1~1, 
a2131) were inactive. These data are in agreement with inde- 
pendent experiments howing that transfection of Chinese 
hamster ovary (CHO) cells with cDNAs for the human ctV- 
and [~3-integrin chains confers on them the ability to bind to 
the rF6 fragment (Martin Pfaff and Joe Loftus, unpublished 
results)• cW[~3 expression in an active form is therefore suffi- 
cient to allow cells to adhere to fibrillin-1. However, it is 
possible that other integrins also recognize the single RGD 
motif in fibrillin-1. This would explain our failure to get com- 
plete inhibition of 251MG cell adhesion to rF6 with inhibitory 
anti-~3-integrin a tibodies• The integrin-binding properties of 
fibrillin-1 resemble those of another extracellular matrix pro- 
tein, osteopontin. It is recognized by integrins txV~3 and also 
ctV[35 and ctV[31 [26], but not by integrin ctIIb133 [27]. Yet 
most other RGD proteins uch as fibronectin, vitronectin or 
the laminin-P1 fragment bind to both ctIIb[33 and aV[33 [21], 
and some of them, like mouse fibulin-2, bind distinctly better 
to t~IIb[33 than to cW~3 [20]. 
In the inhibition experiments fragment rF2 was a more 



























concentration for coating, gg/ml 
Fig. 2. Cell attachment of A375 melanoma (A) and HT1080 fibro- 
sarcoma (B) cells to vitronectin (open squares), rF6trunc (closed cir- 
cles) and rF11 (open circles). 
tide, whereas both the peptide and the recombinant protein 
were similarly active in the solid phase binding assay with 
integrin ~V[33 (Tables 2 and 3). This might be explained by 
the different experimental conditions in both assays leading to 
different states of activation of integrins and to a preferential 
stabilization of the larger recombinant protein bound to the 
integrin in the plasma membrane. 
Interestingly, the three RGD nonapeptides representing the 
three RGD sites of fibrillin-1 and fibrillin-2 inhibit integrin 
~V[~3 as well as cdIb[53 and ~5131 in solid phase binding 
assays, although with about 20-fold reduced activity com- 
pared to GRGDS (Table 3). This implies that the structural 
information conferring specificity for integrin ctV[53 is present 
in the recombinant fibrillin-1 proteins but not in the nonapep- 
tides. Therefore no conclusions on integrin-specific binding 
activities of fibrillin-2 can be extrapolated from experiments 
with short linear peptides. 
Some insight into the molecular criteria that determine 
binding specificities of RGD ligands to integrins etV[~3, 
ctIIb133 and a5~ll can be obtained by a comparison of the 
inhibitory activity of soluble GRGDS peptide with the con- 
centrations of soluble ligands in solid phase assays (Table 3; 
see also [28]). Whereas inhibitory GRGDS concentrations for 
integrin cW[~3 are within the range of the vitronectin concen- 
Table 3 
Inhibition of binding to immobilized integrins with GRGDS, RGD nonapeptides corresponding to authentic sequences of fibrillin-1 and -2 and 
recombinant fragment rF2 
Integrirdsoluble ligand GRGDS Fb-1 Fb-2/2 Fb-2/1 rF2 
cW!~3 (1.5 gg/ml) 
vitronectin (65 nM) 0.035 0.57 1.7 3.1 0.18 
rF6trunc (280 nM) 0.031 0.30 n.d. n.d. 0.13 
cdIb[33 (3 gg/ml) 
fibrinogen (30 nM) 6.1 92 53 78 n.d. 
fibronectin (20 nM) 0.58 9.1 n.d. n.d. >>20 
c~5~1 (0.5 gg/ml) 
fibronectin (20 nM) 4.7 103 85 252 n.d. 
n.d.=not determined. Results are expressed as IC50 values (gM). Numbers in brackets indicate concentrations used for coating (integrins) or 
soluble concentrations (ligands). Peptides representing RGD sites of fibrillins were IRPRGDNGD (Fb-1), FGPRGDGSL (Fb-2/2) and 
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Fig. 3. Binding of fibrinogen (open diamonds), vitronectin (open 
squares), and recombinant fibrillin-1 peptides rF6 (closed circles) 
and rFl l  (open circles) to immobilized integrins etlIb133 (A) and 
aVl~3 (B). 
tration, IC~0 values for integrins c~Ilbl~3 and cc5131 are two 
orders of magnitude higher than the concentrations of their 
soluble ligands. Therefore, the relative contribution of the 
RGD sequence alone to the overall binding affinity strongly 
differs between these integrins, and the simple presence of an 
appropriately exposed RGD motif might be sufficient o med- 
iate binding of ~VI]3. In contrast, recognition by integrins 
alIb133 and c~5131 seems to require additional binding criteria, 
as exemplified by the well-defined synergy region in fibronec- 
tin [29]. The absence of such additional binding structures in 
fibrillin-1 might thus explain an insufficient affinity for integ- 
rins ~Ilbl~3 and c~5131. 
Although it still remains to be shown that the RGD site of 
fibrillin-1 is similarly accessible in authentic fibrillin-1 mole- 
cules, our results convincingly demonstrate its correct expo- 
sure in recombinant fragments of fibrillin-1 for binding to a 
subset of RGD-dependent integrins. The putative physiologi- 
cal role of fibrillin-cell interactions i presently unclear. They 
could provide a structural link between the cytoskeleton of 
cells, microfibrils and elastic fibers. In fact, fibrillin has been 
identified by immunoelectron microscopy in microfibrils that 
connect elastic fibers to cytoskeletal structures in endothelial 
cells [10]. In addition, the assembly of microfibrils and elastic 
fibers might depend on fibrillin interactions with cells. Elastic 
fiber assembly typically occurs at infoldings of the cell surface, 
where microfibrils are seen close to the cell membrane [30]. 
Specific binding of integrin c~VI33 to fibrillin-1 may also play 
an important role during angiogenesis. The key role played by 
c~V133 expressed on endothelial cells in this process [31], to- 
gether with the abundance of fibrillin-1 in the vascular wall 
and in the surrounding connective tissue, underlines this pos- 
sibility. 
5. Note added in proof 
During the submission of the manuscript, a report appeared 
[32] describing cellular interactions mediated by integrin ccVI33 
to fibrillin-1 purified from bovine tissues. 
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